[
  {
    "ts": "2026-02-02T13:00:00+00:00",
    "headline": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
    "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
    "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e920c1bc-d19b-3b4f-b932-72c10c3f9f9b",
      "content": {
        "id": "e920c1bc-d19b-3b4f-b932-72c10c3f9f9b",
        "contentType": "STORY",
        "title": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
        "description": "",
        "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
        "pubDate": "2026-02-02T13:00:00Z",
        "displayTime": "2026-02-02T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GXCxbsFDDz3fFTI03HwuBw--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qhQKh0p3toIAfsx9SijYTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T14:51:53+00:00",
    "headline": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
    "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "324c2382-0838-398c-97b0-5298c2375c4d",
      "content": {
        "id": "324c2382-0838-398c-97b0-5298c2375c4d",
        "contentType": "STORY",
        "title": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
        "pubDate": "2026-02-02T14:51:53Z",
        "displayTime": "2026-02-02T14:51:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V.cYaSHzzKzVHdGmA_7kFQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WQYQ_aVrFtQIDc0.PoEAUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T15:34:00+00:00",
    "headline": "Buy AbbVie Stock Before Q4 Earnings? Here's What to Know",
    "summary": "ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.",
    "url": "https://finance.yahoo.com/news/buy-abbvie-stock-q4-earnings-153400869.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bac30681-9493-3b93-86eb-46b21d740103",
      "content": {
        "id": "bac30681-9493-3b93-86eb-46b21d740103",
        "contentType": "STORY",
        "title": "Buy AbbVie Stock Before Q4 Earnings? Here's What to Know",
        "description": "",
        "summary": "ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.",
        "pubDate": "2026-02-02T15:34:00Z",
        "displayTime": "2026-02-02T15:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-abbvie-stock-q4-earnings-153400869.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-abbvie-stock-q4-earnings-153400869.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T15:25:00+00:00",
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
    "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-152500776.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "71a7afb9-ce36-3cc9-a1ec-379d4ecc1950",
      "content": {
        "id": "71a7afb9-ce36-3cc9-a1ec-379d4ecc1950",
        "contentType": "STORY",
        "title": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
        "description": "",
        "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
        "pubDate": "2026-02-02T15:25:00Z",
        "displayTime": "2026-02-02T15:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/44f6a0d2318749b70fea99c7e1845c48",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tTGp.ukDgQsfJ2wtQbOlpQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/44f6a0d2318749b70fea99c7e1845c48.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EgPFAUyZvvJjYrTV0pc.LQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/44f6a0d2318749b70fea99c7e1845c48.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-152500776.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-152500776.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "DX-Y.NYB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T16:40:24+00:00",
    "headline": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "url": "https://247wallst.com/investing/2026/02/02/merck-reports-earnings-tuesday-morning-after-gaining-13-over-the-past-year/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "72a067da-b0cb-36a3-ad1f-ff5a7d524ab5",
      "content": {
        "id": "72a067da-b0cb-36a3-ad1f-ff5a7d524ab5",
        "contentType": "STORY",
        "title": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
        "description": "",
        "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
        "pubDate": "2026-02-02T16:40:24Z",
        "displayTime": "2026-02-02T16:40:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/6781d7d3979220d8fe685cda4dbf3472",
          "originalWidth": 1376,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iUMo9g7jHZMXDjtBcjD1Rg--~B/aD03Njg7dz0xMzc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/6781d7d3979220d8fe685cda4dbf3472.cf.webp",
              "width": 1376,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ydaDuqi80TRZFHI6PmO_3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/6781d7d3979220d8fe685cda4dbf3472.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/02/merck-reports-earnings-tuesday-morning-after-gaining-13-over-the-past-year/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-reports-earnings-tuesday-morning-164024455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]